A significant proportion of HER2‐positive EC will be misclassified if the breast cancer‐specific HER2 testing guidelines are applied, because incomplete membranous staining in breast cancer is classified as IHC‐1+ and considered to be HER2‐negative. This evidence concerns the gene ERBB2 and breast carcinoma.